Menlo Park, California-based Personalis (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, reported unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.
Full-year total revenue is expected in the range of $69 million to $70 million, compared with $84.6 million in 2024.
The decline primarily reflects changes in the mix of revenue streams, partially offset by robust growth in clinical testing.
Clinical momentum accelerated sharply, with clinical test revenue reaching approximately $2 million, more than doubling the $0.8 million recorded in 2024.
Clinical test volume surged to approximately 16,233 tests, a nearly 400% increase over the 3,285 tests delivered in the prior year.
This outperformance exceeded the company's internal growth targets by more than 20%, highlighting growing market adoption of its ultrasensitive minimal residual disease (MRD) testing platform.
Revenue from pharma tests, services, and other customers contributed approximately $49 million to $50 million, while enterprise sales to Natera and population sequencing for the U.S. Department of Veterans Affairs Million Veterans Program totaled approximately $18 million.
For the fourth quarter alone, revenue is anticipated in the range of $17 million to $18 million.
The company delivered 6,183 clinical tests, representing a 41% sequential increase from the third quarter of 2025.
Preliminary clinical test revenue reached approximately $0.9 million, compared with $0.2 million in the year-ago quarter.
Pharma tests, services, and other customers contributed approximately $11.6 million to $12.6 million, with enterprise and population sequencing revenue at approximately $4.5 million.
Personalis ended the year with a strong liquidity position of approximately $240 million in cash, cash equivalents, and short-term investments, bolstered by roughly $109 million in net proceeds from its at-the-market sales program at a weighted-average price of $8.43 per share.